Introduction
============

Severe acute pancreatitis (SAP) is a serious systemic inflammatory disease with high mortality rate, which may cause systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) due to excessive inflammatory reactions. However, the exact pathogenesis remains unclear ([@b1-etm-0-0-2802]). Studies have found that nuclear factor κB (NF-κB) has a high level of expression in SAP, and plays an important role in regulating the inflammatory response ([@b2-etm-0-0-2802],[@b3-etm-0-0-2802]). Tumor necrosis factor (TNF)-α is an inflammatory mediator that is also plays a critical role in the pathogenesis of acute pancreatitis by driving the subsequent inflammatory response ([@b4-etm-0-0-2802]). Ulinastatin is a purified antiprotease isolated from the fresh urine of healthy adults, which possesses powerful anti-inflammatory effects and has been demonstrated to exert significant therapeutic effects in several forms of acute pancreatitis ([@b5-etm-0-0-2802],[@b6-etm-0-0-2802]). However, the impact of ulinastatin administered by peritoneal lavage on the expression levels of NF-κB and TNF-α in multiple organs in SAP has not been studied. According to our preliminary study ([@b7-etm-0-0-2802]), peritoneal lavage with the addition of ulinastatin at a concentration of 62.5 U/ml to the lavage fluid exerts the best therapeutic effect. The present study investigated the expression levels of NF-κB and TNF-α in multiple organs and thereby explored the underlying mechanism of intraperitoneal lavage with ulinastatin on a rat model of SAP. The results may provide convincing theoretical evidence supporting the further experimental and clinical application of ulinastatin as a peritoneal lavage.

Materials and methods
=====================

### Experimental animals and ethics

A total of 100 healthy male Wistar rats weighing 300±15 g were obtained from the Experimental Animal Center of the PLA General Hospital (Beijing, China). The experimental protocol was approved by the Ethics Committee for Animal Research from the PLA General Hospital. Ethical standards were adhered to and the rats received humane care.

### Reagents

Reagents were purchased as follows: Chloral hydrate (Shanghai Yingxin Laboratory Equipment Co., Ltd., Shanghai, China); sodium taurocholate (Shanghai Hufeng Biotechnology Co., Ltd., Shanghai, China); ulinastatin (Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd., Guangzhou, China); IL-1 and IL-6 assay kits (Shanghai Hengyuan Biological Technology Co., Ltd., Shanghai, China); and rat soluble NF-κB and TNF-α ELISA kits (Wuhan Hua Mei Biological Engineering Co., Ltd., Wuhan, China).

### Experimental groups

Rats were randomly divided into five groups: Group C (n=20), sham-operated without induction of SAP, peritoneal lavage or intravenous injection, but with insertion of a catheter; group SAP (n=20), induction of SAP without peritoneal lavage or intravenous injection, but with insertion of a catheter; group SL (n=20), saline lavage for 3 h immediately after the induction of SAP; group IU (n=20), intravenous ulinastatin at 2,500 U/100 g immediately after the induction of SAP and with insertion of a catheter, but without peritoneal lavage; group UL (n=20), ulinastatin lavage at a concentration of 62.5 U/ml for 3 h immediately after the induction of SAP.

### Animal model

All rats fasted for 12 h and had no water for 4 h prior to surgery. Rats were anesthetized with intraperitoneal injections of 10% chloral hydrate (3 ml/kg). After making an incision in the abdomen, clamping the opening and remote part of the duodenal bile duct with injury-free metal clips, a syringe needle was inserted into the opening of the duodenal bile duct. Then, 5% sodium taurocholate (freshly prepared in saline solution, 0.6 ml) was retrogradely injected into the bile duct at constant rate of 0.2 ml/min using an infusion pump. After 5 min, the needle and metal clips were removed. This procedure produces a consistently high mortality rate (\>80% within 12 h) ([@b8-etm-0-0-2802]). Group C was sham-operated without induction of SAP.

Prior to closure of the abdomen, a silicon catheter (catheter A) with five lateral outlets was placed adjacent to the pancreas and another silicon catheter (catheter B) with five lateral outlets was placed in the pelvic cavity. All groups accepted peritoneal catheter insertion.

### Peritoneal lavage

Intraperitoneal lavage was performed immediately following the establishment of the SAP model in the rats of groups SL and UL. Lavage fluid was warmed to 37°C and injected from catheter A at 80 ml/h for 15 min and catheter B was blocked. Then, catheter A was blocked and the fluid was allowed to flow out for 15 min from catheter B. Thus, each lavage procedure lasted 30 min, and lavage was performed 6 times (3 h total lavage time). Volume input and output were monitored. The lavage fluid consisted of saline solution with or without the addition of ulinastatin at a concentration of 62.5 U/ml, which our earlier study indicated to exert the optimum therapeutic effect. Following the lavage procedure, the catheters A and B were blocked and the rats were kept in single cages, with free access to water and no solid food.

### Intravenous ulinastatin

To compare the effect of peritoneal lavage with that of intravenously administered ulinastatin, group IU immediately received intravenous ulinastatin 2,500 U/100 g (freshly prepared in 0.15 ml saline solution, which approximates the total dose in group UL) from the caudal vein after SAP induction, but no lavage.

### Observation indices

The survival time of each group (n=10 for each) was recorded for 12 h and the survival rate at 3, 6, 9 and 12 h was calculated. Rats surviving to 12 h were anesthetized and sacrificed humanely. At 3 h after surgery, rats in each group (n=10 for each) were also humanely sacrificed, and blood samples were collected for the detection of inflammatory mediators (including IL-1 and IL-6), and specimens of multiple organs (including pancreas, lung, liver and kidney) were prepared for determination of the expression levels of NF-κB and TNF-α.

All tissues were homogenized with cold saline at a 1:9 dilution using a PowerGen 1000 homogenizer (Thermo Fisher Scientific, Waltham, MA, USA). All tissue specimens were rinsed in cold saline to remove blood, dried with filter paper, cut into small pieces using a disposable scalpel, and 0.4 g tissue (pancreas, lung, live or kidney) was added to a 10-ml beaker. Next, 3.6 ml cold saline was added to the tissue and homogenization was achieved by using the homogenizer for 1--2 min. Subsequently, 10% homogenate was prepared using low temperature centrifugation at 1,000 × g for 10--15 min at 4°C and the supernatant was obtained for determination.

### Assays for serum IL-1, IL-6 content and supernatant of homogenate NF-κB and TNF-α expression levels

Samples for IL-1, IL-6, NF-κB and TNF-α were aliquoted in portions and stored at −80°C for no longer than 2 months. Measurements were performed using the IL-1, IL-6, rat soluble NF-κB and TNF-α ELISA kits and a standard ELISA reader according to the manufacturers instructions.

### Statistical analysis

Data are expressed as mean ± standard deviation for normally distributed variables or median and interquartile range for highly skewed variables. Statistical analyses were performed using the SPSS software package, version 19.0 (SPSS, Inc., Chicago, IL, USA).

In survival experiments, the survival rate after the 12 h observation period was conducted by the Kaplan-Meier or Kruskal-Wallis H test. Analysis of variance was used for comparison of normally distributed data. Multiple comparisons were subjected to Kruskal-Wallis H test and Bonferroni correction test. The Chi-square test was used to evaluate the equality of frequencies for discrete variables. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Survival rate

All rats in group C were alive at 12 h (100%). At 6 h, group SAP had a survival rate of 20% and the survival rates in groups SL (50%), IU (60%) and UL (100%) were all increased compared with that in group SAP. However, at 9 h, only group UL (50%) had a greatly increased survival rate compared with that in than groups SAP (10%), SL (20%) and IU (20%). At 12 h, there was no difference in survival rate among groups SAP (0%), SL (0%), IU (0%) and UL (10%). The results are summarized in [Table I](#tI-etm-0-0-2802){ref-type="table"}.

### Inflammatory mediators

The plasma levels of IL-1 and IL-6 in the rats of group SAP were significantly increased compared with those in group C. The levels of IL-1 in groups SL, IU and UL were significantly reduced compared with those in group SAP. The lowest levels of IL-1 were observed in group UL ([Fig. 1](#f1-etm-0-0-2802){ref-type="fig"}). Compared with the IL-6 levels in group SAP, those in groups IU and UL were significantly reduced, and the strongest effect was observed in group UL, but group SL did not exhibit a statistically significant difference ([Fig. 1](#f1-etm-0-0-2802){ref-type="fig"}). The results are summarized in [Table II](#tII-etm-0-0-2802){ref-type="table"}.

### Expression levels of TNF-α in multiple organs

The expression levels of TNF-α in the pancreas, lung, liver and kidney of rats in group SAP were significantly increased compared with those in group C. In groups SL, IU and UL, the expression levels of TNF-α in the pancreas were significantly reduced compared with those in group SAP, and groups SL and UL exhibited greater reductions in TNF-α levels than group IU ([Fig. 2A](#f2-etm-0-0-2802){ref-type="fig"}). The expression levels of TNF-α in the lungs of rats in groups SL, IU and UL were significantly reduced compared with those in group SAP, and the TNF-α levels in group UL were the lowest among these three groups ([Fig. 2B](#f2-etm-0-0-2802){ref-type="fig"}). The expression levels of TNF-α in the livers of the rats in groups SL, IU and UL were significantly reduced compared with those in group SAP. The effects in groups UL and SL were comparable and stronger than those in group IU ([Fig. 2C](#f2-etm-0-0-2802){ref-type="fig"}). The expression levels of TNF-α in the kidneys of the rats in groups SL, IU and UL were significantly reduced compared with those in group SAP, and were reduced to the greatest extent in group UL ([Fig. 2D](#f2-etm-0-0-2802){ref-type="fig"}). The results are summarized in [Table III](#tIII-etm-0-0-2802){ref-type="table"}.

### Expression levels of NF-κB in multiple organs

The expression levels of NF-κB in the pancreas, lung, liver and kidney of rats in group SAP were significantly greater than those in group C. In groups SL and UL, the expression levels of NF-κB in the pancreas were significantly reduced compared with those in group SAP, but those of group IU were not. The effects observed in group SL were almost the same as those in group UL ([Fig. 3A](#f3-etm-0-0-2802){ref-type="fig"}). The expression levels of NF-κB in the lungs of rats in groups SL, IU and UL were significantly reduced compared with those in group SAP, with group UL exhibited the greatest reduction ([Fig. 3B](#f3-etm-0-0-2802){ref-type="fig"}). The expression levels of NF-κB in the livers of the rats in groups SL, IU and UL were significantly reduced compared with those in group SAP. The effects observed in groups UL and SL were greater than those in group IU ([Fig. 3C](#f3-etm-0-0-2802){ref-type="fig"}). The expression levels of NF-κB in the kidneys of rats in groups SL, IU and UL were significantly reduced compared with those in group SAP. The reduction in group UL was greater than that in groups SL and IU ([Fig. 3D](#f3-etm-0-0-2802){ref-type="fig"}). The results are summarized in [Table IV](#tIV-etm-0-0-2802){ref-type="table"}.

Discussion
==========

SAP is a systemic disease with a high mortality rate, which may induce SIRS and MODS due to the excessive inflammatory reactions that play an important role in the pathogenesis of SAP. It has been reported that pancreatic enzymes released into the peritoneal exudate could aggravate the inflammatory condition by damaging multiple organs ([@b1-etm-0-0-2802],[@b9-etm-0-0-2802]). Therefore, peritoneal lavage and antiprotease therapy may bring an improved therapeutic effect through being applied locally to the peritoneal cavity ([@b10-etm-0-0-2802]). The glycoprotein ulinastatin is widely used to treat patients with SAP via the intravenous route ([@b11-etm-0-0-2802],[@b12-etm-0-0-2802]); one of its therapeutic functions is regulation of the inflammatory response. Ulinastatin may provide a greater therapeutic effect for SAP if administered by peritoneal lavage as only a small amount of intravenously administered ulinastatin is able to reach the pancreas and other organs because of microcirculatory dysfunction ([@b13-etm-0-0-2802]).

Studies of SAP treatment by ulinastatin-containing peritoneal lavage have rarely been reported. However, on the basis of our previous study, peritoneal lavage with the addition of 62.5 U/ml ulinastatin to the lavage fluid provides the optimum effect in the treatment of SAP. In the survival experiment conducted in the present study, group UL exhibited the greatest median survival rate among the four treatment groups at 6 and 9 h. Ulinastatin administered intravenously or by peritoneal lavage improved the survival rate; however, peritoneal lavage with ulinastatin provided the greatest effect.

IL-1 and IL-6 are significant proinflammatory cytokines that are present at elevated levels in the pathogenesis of acute pancreatitis and play a critical role in mediating the systemic inflammatory response ([@b14-etm-0-0-2802],[@b15-etm-0-0-2802]). It has been reported that the levels of proinflammatory cytokines correlate with the severity of acute pancreatitis ([@b16-etm-0-0-2802]). The present study demonstrated that the serum levels of IL-1 and IL-6 in group SAP were significantly elevated compared with those in group C. Following treatment, the levels of IL-1 and IL-6 in group UL were much lower than those in group SAP and were also lower than those in groups SL and IU. This indicated that the administration of ulinastatin by peritoneal lavage most effectively lowered the levels of inflammatory mediators in the serum, alleviated the severe systemic inflammatory response and inhibited the progress of SAP by inhibiting the release of inflammatory mediators.

TNF-α is considered to be one of the major factors associated with the multiple tissue or organ damage caused by a systemic inflammatory response and could be a therapeutic target for therapeutic applications in SAP ([@b17-etm-0-0-2802]). The results of the present study showed that the levels of TNF-α in multiple organs of group SAP were greater than those in group C. After treatment, the expression levels of TNF-α in the pancreas, lung, liver, and kidney of group UL were significantly lower than those in groups SL and IU. This indicated that saline lavage with ulinastatin protected multiple organs from further damage through inhibiting TNF-α to attenuate the systemic inflammatory response. The results for the serum levels of IL-1 and IL-6 in the present study are consistent with this.

A number of studies have demonstrated that the activation of NF-κB plays a significant role in the onset of SAP, due to its ability to regulate the expression of inflammatory mediators ([@b16-etm-0-0-2802],[@b18-etm-0-0-2802]). The activation of NF-κB has been shown to increase the expression of TNF-α ([@b19-etm-0-0-2802]). In the present study, following the induction of SAP, it was observed that NF-κB was activated significantly in multiple organs of the rats in group SAP compared with group C; the expression of TNF-α in the various organs from group SAP also increased markedly. Peritoneal lavage with ulinastatin significantly reduced the expression of NF-κB in multiple organs; among the groups SL, IU and UL, the greatest effects were observed in group UL. The trend of changes in TNF-α in multiple organs was similar to that of NF-κB among groups SAP, SL, IU and UL. Therefore, it can be inferred that peritoneal lavage with ulinastatin alleviates the inflammatory response and progression of SAP by inhibiting the activation of NF-κB. This may lower the expression of TNF-α, thereby reducing the release of IL-1 and IL-6.

In conclusion, this study provides evidence that peritoneal lavage with ulinastatin may effectively improve the prognosis of SAP by mitigating the extent of inflammation, specifically by inhibiting NF-κB activation, lowering the expression of TNF-α and reducing the levels of IL-1 and IL-6. The results in this study may provide a basis for further experimental or clinical research into SAP.
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![Effect of peritoneal lavage with ulinastatin on inflammatory mediators. The levels of (A) IL-1 and (B) IL-6 in group SAP were significantly increased compared with those in group C. Groups SL, IU and UL all exhibited reduced levels of IL-1 and IL-6 compared with those in group SAP. Moreover, group UL had lower levels of IL-1 and IL-6 than groups SL and IU. \*P\<0.05, \*\*P\<0.01. C, control; SAP, severe acute pancreatitis; SL, saline lavage; IU, intravenous ulinastatin; UL, ulinastatin lavage; IL, interleukin.](etm-10-06-2029-g00){#f1-etm-0-0-2802}

![Comparison of different treatments on the expression levels of TNF-α in the (A) pancreas, (B) lung, (C) liver and (D) kidney. The expression levels of TNF-α in multiple organs were greatly increased in group SAP compared with those in group C. The treatments administered to groups SL, IU and UL all significantly decreased the expression levels of TNF-α in multiple organs compared with those in group SAP and group UL exhibited the greatest reduction in expression levels. \*P\<0.05, \*\*P\<0.01. C, control; SAP, severe acute pancreatitis; SL, saline lavage; IU, intravenous ulinastatin; UL, ulinastatin lavage; TNF-α, tumor necrosis factor-α.](etm-10-06-2029-g01){#f2-etm-0-0-2802}

![Comparison of different treatments on the expression levels of NF-κB in the (A) pancreas, (B) lung, (C) liver and (D) kidney. The expression levels of NF-κB in multiple organs were greatly increased in group SAP compared with those in group C. Compared with the NF-κB levels in group SAP, those in groups SL, IU and UL were significantly decreased and group UL exhibited the greatest reduction in NF-κB levels. \*P\<0.05, \*\*P\<0.01. C, control; SAP, severe acute pancreatitis; SL, saline lavage; IU, intravenous ulinastatin; UL, ulinastatin lavage; NF-κB, nuclear factor-κB.](etm-10-06-2029-g02){#f3-etm-0-0-2802}

###### 

Comparison of survival rate among the five groups (each n=10).

          Survival rate (%)                                                                                                                                                                                                                              
  ------- ------------------- --------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------ -----------------------------------------------------------
    3 h   10/10 (100)         9/10 (90)                                                 10/10 (100)                                               10/10 (100)                                                                                            10/10 (100)
    6 h   10/10 (100)         2/10 (20)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^   5/10 (50)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^   6/10 (60)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"},[b](#tfn2-etm-0-0-2802){ref-type="table-fn"}^   10/10 (100)^[b](#tfn2-etm-0-0-2802){ref-type="table-fn"}^
    9 h   10/10 (100)         1/10 (10)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^   2/10 (20)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^   2/10 (20)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^                                                5/10 (50)^[b](#tfn2-etm-0-0-2802){ref-type="table-fn"}^
  12 h    10/10 (100)         0/10 (0)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^    0/10 (0)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^    0/10 (0)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^                                                 1/10 (10)^[a](#tfn1-etm-0-0-2802){ref-type="table-fn"}^

P\<0.05 compared with group C;

P\<0.05 compared with group SAP. C, control; SAP, severe acute pancreatitis; SL, saline lavage; IU, intravenous ulinastatin; UL, ulinastatin lavage.

###### 

Effect of the different treatments on inflammatory mediators.

  Mediator       C             SAP                                                          SL                                                                                                       IU                                                                                                        UL
  -------------- ------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- -----------------------------------------------------------
  IL-1 (ng/ml)   0.047±0.016   0.182±0.047^[a](#tfn4-etm-0-0-2802){ref-type="table-fn"}^    0.102±0.027^[a](#tfn4-etm-0-0-2802){ref-type="table-fn"},[b](#tfn5-etm-0-0-2802){ref-type="table-fn"}^   0.105±0.039^[a](#tfn4-etm-0-0-2802){ref-type="table-fn"},[b](#tfn5-etm-0-0-2802){ref-type="table-fn"}^    0.071±0.028^[b](#tfn5-etm-0-0-2802){ref-type="table-fn"}^
  IL-6 (pg/ml)   56.19±13.08   129.15±35.85^[a](#tfn4-etm-0-0-2802){ref-type="table-fn"}^   111.35±20.38^[a](#tfn4-etm-0-0-2802){ref-type="table-fn"}^                                               108.73±34.96^[a](#tfn4-etm-0-0-2802){ref-type="table-fn"},[c](#tfn6-etm-0-0-2802){ref-type="table-fn"}^   71.34±15.28^[b](#tfn5-etm-0-0-2802){ref-type="table-fn"}^

Values are presented as mean ± standard deviation.

P\<0.01 vs. group C;

P\<0.01,

P\<0.05 vs. group SAP. C, control; SAP, severe acute pancreatitis; SL, saline lavage; IU, intravenous ulinastatin; UL, ulinastatin lavage.

###### 

Effect of different treatment on the expression levels of TNF-α in multiple organs at 3 h (pg/ml).

  Organ      C               SAP                                                          SL                                                                                                         IU                                                                                                         UL
  ---------- --------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Pancreas     4.497±0.275   12.153±0.398^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"}^     5.535±0.260^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^     6.651±0.213^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^     5.287±0.334^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^
  Lung       11.126±1.513    21.383±1.834^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"}^   14.219±1.002^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^    15.670±1.614^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^    12.870±1.412^[b](#tfn9-etm-0-0-2802){ref-type="table-fn"},[c](#tfn10-etm-0-0-2802){ref-type="table-fn"}^
  Liver      11.079±0.566    25.054±0.605^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"}^   12.797±0.842^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^    15.009±0.866^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^    12.929±0.745^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^
  Kidney       9.587±0.405   14.566±0.355^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"}^   10.802±0.538^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^    12.403±0.731^[b](#tfn9-etm-0-0-2802){ref-type="table-fn"},[c](#tfn10-etm-0-0-2802){ref-type="table-fn"}^   10.082±0.436^[a](#tfn8-etm-0-0-2802){ref-type="table-fn"},[b](#tfn9-etm-0-0-2802){ref-type="table-fn"}^

Values are presented as mean ± standard deviation.

P\<0.01 vs. group C;

P\<0.01 vs. group SAP;

P\<0.05 vs. group C. C, control; SAP, severe acute pancreatitis; SL, saline lavage; IU, intravenous ulinastatin; UL, ulinastatin lavage; TNF-α, tumor necrosis factor.

###### 

Effect of different treatments on the expression levels of NF-κB in multiple organs at 3 h (pg/ml).

  Organ      C             SAP                                                          SL                                                                                                         IU                                                                                                         UL
  ---------- ------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------
  Pancreas   3.198±0.295   4.424±0.153^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"}^   3.716±0.266^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[b](#tfn13-etm-0-0-2802){ref-type="table-fn"}^   4.254±0.166^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"}^                                                 3.574±0.297^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[b](#tfn13-etm-0-0-2802){ref-type="table-fn"}^
  Lung       4.543±0.349   6.821±0.276^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"}^   5.215±0.300^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[b](#tfn13-etm-0-0-2802){ref-type="table-fn"}^   5.890±0.359^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[b](#tfn13-etm-0-0-2802){ref-type="table-fn"}^   4.856±0.285^[b](#tfn13-etm-0-0-2802){ref-type="table-fn"},[c](#tfn14-etm-0-0-2802){ref-type="table-fn"}^
  Liver      3.489±0.257   6.250±0.384^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"}^   3.781±0.276^[b](#tfn13-etm-0-0-2802){ref-type="table-fn"},[c](#tfn14-etm-0-0-2802){ref-type="table-fn"}^   4.766±0.334^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[b](#tfn13-etm-0-0-2802){ref-type="table-fn"}^   3.793±0.223^[b](#tfn13-etm-0-0-2802){ref-type="table-fn"},[c](#tfn14-etm-0-0-2802){ref-type="table-fn"}^
  Kidney     2.690±0.277   5.568±0.297^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"}^   4.665±0.267^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[b](#tfn13-etm-0-0-2802){ref-type="table-fn"}^   5.225±0.325^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[d](#tfn15-etm-0-0-2802){ref-type="table-fn"}^   3.878±0.329^[a](#tfn12-etm-0-0-2802){ref-type="table-fn"},[b](#tfn13-etm-0-0-2802){ref-type="table-fn"}^

Values are presented as mean ± standard deviation.

P\<0.01 vs. group C;

P\<0.01 vs. group SAP;

P\<0.05 vs. group C;

P\<0.05 vs. group SAP. C, control; SAP, severe acute pancreatitis; SL, saline lavage; IU, intravenous ulinastatin; UL, ulinastatin lavage; NF-κB, nuclear factor-κB.

[^1]: Contributed equally
